Cognis delighted about DHA and Vitamin E claim approvals - assessment for its CLA claim still pending
The EFSA's third batch of article 13.1 health claim opinions included good news for Cognis. There were three positive opinions on health claims concerning DHA - claims relating to normal brain function, normal vision, and maintaining normal (fasting) blood concentrations of triglycerides were all upheld - and various health claims for Vitamin E were also approved, relating to its ability to protect DNA, proteins and lipids against oxidative damage.
While the EFSA panel rejected some health claims relating to conjugated linoleic acid (CLA), it did not give any specific opinion about the relationship between CLA and body fat reduction. Cognis' Tonalin® CLA is marketed not as a weight loss ingredient, but rather as an ingredient for body fat reduction - a benefit that has been proven in numerous human studies, conducted to the strictest standards and designed using double-blind randomization and placebo control. "This is why we will review the opinion in detail and raise our concerns with the European Commission to clarify whether our claims will be evaluated in a later batch," says Dr. Arne Ptock, Global Product Line Manager Tonalin®, Cognis Nutrition & Health.
BASF Personal Care and Nutrition GmbH
Cognis is a worldwide supplier of specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 5,500 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and provides value adding solutions and products based on renewable raw materials. The company serves the food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, as well as agriculture and mining.
Cognis is currently owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2009, Cognis recorded sales of about 2.6 billion euros and an Adjusted EBITDA (operating result) of 364 million euros.